Pulmonary Intravascular Macrophages Metabolize Arachidonic AcidIn Vitro: Comparison with Alveolar Macrophages
- 1 October 1988
- journal article
- research article
- Published by American Thoracic Society in American Review of Respiratory Disease
- Vol. 138 (4) , 936-944
- https://doi.org/10.1164/ajrccm/138.4.936
Abstract
Pulmonary intravascular macrophages are a recently identified component of the pulmonary mononuclear phagocyte system. It has been shown that alveolar macrophages are capable of metabolizing arachidonic acid (AA) to its biologically active inflammatory metabolites via the lipoxygenase and cyclooxygenase pathways. In this study, we have compared the ability of swine intravascular macrophages and alveolar macrophages to metabolize AA in vitro. Alveolar macrophages attached to a plastic substrate produced at least five identified AA metabolites including prostaglandin (PG)F2a, hydroxyheptadecatrienoic acid (HHT), 5-hydroxyeicosatetraenoic acid (HETE), 12-HETE, and 15-HETE. In contrast, adherent intravascular macrophages produced eight identified metabolites including thromboxane (TX)B2, PGF2a, PGD2, PGE2, HHT, 5-HETE, 12-HETE, and 15-HETE. The major lipoxygenase metabolite produced by both macrophage types was 5-HETE. The major cyclooxygenase metabolite produced by alveolar macrophages was PGF2a, whereas the major metabolite produced by intravascular macrophages was HHT. Both macrophage populations treated with calcium ionophore (A23187) exhibited increased production of PGs, TXB2, leukotriene (LT)B4, 5-HETE, 12-HETE, and 15-HETE, but the most striking increase occurred in metabolism through the lipoxygenase pathway. The major lipoxygenase metabolite generated by ionophore-stimulated macrophages was 5-HETE, and intravascular macrophages 12-HETE was also produced. Preincubation of macrophages with indomethacin and nordihydroguaiaretic acid attenuated the yield of cyclooxygenase metabolites and lipoxygenase metabolites, respectively. Studies of leukotriene formation demonstrated that both macrophage types produce LTC4 and LTB4 from the leukotriene precursor LTA4. Thus, we show that the pulmonary intravascular macrophage is capable of metabolizing AA and LTA4 to their inflammatory and vasoactive metabolites by the cyclooxygenase and lipoxygenase pathways. The intravascular macrophage appears to be more active metabolically than the alveolar macrophage when stimulated by calcium ionophore. Furthermore, intravascular macrophages, in contrast to alveolar macrophages, contain a 12-lipoxygenase as well as 5-lipoxygenase and cyclooxygenase pathways for metabolizing AA. Further studies are ongoing to test the postulate that intravascular macrophages have a significant role in acute events of pulmonary inflammation and microvascular pressure.This publication has 32 references indexed in Scilit:
- Effect of Exercise on Lung Lymph Flow in Unanesthetized Sheep with Increased Pulmonary Vascular Permeability1–3American Review of Respiratory Disease, 1986
- Monocytic Origin and Postnatal Mitosis of Intravascular Macrophages in the Porcine LungJournal of Leukocyte Biology, 1985
- Arachidonic acid metabolism by human monocytes. Studies with platelet-depleted cultures.The Journal of Experimental Medicine, 1983
- Effects of leukotrienes C4 and D4 on glycoprotein and lysozyme secretion by human bronchial mucosaProstaglandins, 1983
- Human alveolar macrophages produce leukotriene B4.Proceedings of the National Academy of Sciences, 1982
- Secretion of leukotriene C and other arachidonic acid metabolites by macrophages challenged with immunoglobulin E immune complexes.The Journal of Experimental Medicine, 1982
- Regulation of arachidonic acid metabolites in macrophages.The Journal of Experimental Medicine, 1980
- Regulation of the immune response by prostaglandinsClinical Immunology and Immunopathology, 1980
- Influence of sympathetic stimulation and vasoactive substances on the canine pulmonary veins.Journal of Clinical Investigation, 1975